A government-funded network of specialized survivor clinics in Ontario, Canada, significantly decreased emergency department visits among adult survivors of childhood cancer.
A government-funded network of specialized survivor clinics in Ontario, Canada, significantly decreased emergency department (ED) visits among adult survivors of childhood cancer.
Researchers at the University of Toronto devised a population-based, retrospective cohort study to determine the association between prior attendance at survivor clinics by adult survivors of pediatric cancer and ED use. Data from survivors diagnosed with cancer during the period between January 1, 1986, and December 31, 2005, were included in the study published in the journal Cancer.
Of the more than 3900 participants in the study, those who had had at least 1 prior visit to a survivor clinic had a 19% reduction in rate of ED visits compared with individuals who had not visited a survivor clinic (adjusted relative rate, 0.81; 95% confidence interval (CI), 0.78-0.85). Every additional visit to the survivor clinic decreased the rate of ED utilization even further.
“The growing number of childhood cancer survivors has reached a tipping point that has compelled the creation of a clinical field focused on survivor care,” said senior author Paul Nathan, MD, MSc, FRPC, director of a survivor program at the Hospital for Sick Children in Toronto. With significantly improved survival among childhood cancer patients, the “quality of the cure” is gaining increased focus from physicians, according to Nathan.
The aim of the survivorship clinics is to provide additional support to pediatric cancer survivors, over and above the care of their oncologist and primary care physician. Their focus, per Nathan, is helping patients identify and address physical and mental health effects that could be associated with the cancer therapy they received several years earlier.
Being patient-centered, these clinics recognize the long-term effects of cancer treatment that can spring up later in life.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More